- Home
- DAWN vs DGICA Comparison
DAWN vs DGICA Comparison
Compare DAWN & DGICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- DGICA
- Stock Information
- Founded
- DAWN 2018
- DGICA 1986
- Country
- DAWN United States
- DGICA United States
- Employees
- DAWN N/A
- DGICA N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- DGICA Property-Casualty Insurers
- Sector
- DAWN Health Care
- DGICA Finance
- Exchange
- DAWN Nasdaq
- DGICA Nasdaq
- Market Cap
- DAWN 624.8M
- DGICA 705.0M
- IPO Year
- DAWN 2021
- DGICA N/A
- Fundamental
- Price
- DAWN $9.14
- DGICA $19.26
- Analyst Decision
- DAWN Strong Buy
- DGICA Hold
- Analyst Count
- DAWN 8
- DGICA 1
- Target Price
- DAWN $27.63
- DGICA $18.00
- AVG Volume (30 Days)
- DAWN 1.9M
- DGICA 121.6K
- Earning Date
- DAWN 11-04-2025
- DGICA 10-30-2025
- Dividend Yield
- DAWN N/A
- DGICA 3.88%
- EPS Growth
- DAWN N/A
- DGICA 219.92
- EPS
- DAWN N/A
- DGICA 2.38
- Revenue
- DAWN $133,672,000.00
- DGICA $987,826,105.00
- Revenue This Year
- DAWN $12.88
- DGICA $2.26
- Revenue Next Year
- DAWN $48.27
- DGICA $3.46
- P/E Ratio
- DAWN N/A
- DGICA $8.09
- Revenue Growth
- DAWN 31.11
- DGICA 0.89
- 52 Week Low
- DAWN $5.64
- DGICA $14.17
- 52 Week High
- DAWN $16.76
- DGICA $21.12
- Technical
- Relative Strength Index (RSI)
- DAWN 71.77
- DGICA 54.19
- Support Level
- DAWN $7.11
- DGICA $18.13
- Resistance Level
- DAWN $7.62
- DGICA $19.49
- Average True Range (ATR)
- DAWN 0.47
- DGICA 0.41
- MACD
- DAWN 0.10
- DGICA -0.03
- Stochastic Oscillator
- DAWN 72.26
- DGICA 83.73
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.